Yun Yen - 30 Jun 2025 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Yun Yen
Issuer symbol
LIXT
Transactions as of
30 Jun 2025
Net transactions value
$0
Form type
4
Filing time
09 Jul 2025, 11:52:58 UTC
Previous filing
02 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Yen Yun Director 680 E. COLORADO BLVD., SUITE 180, PASADENA /s/ Yun Yen 09 Jul 2025 0001684584

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +10,000 $0.000000 10,000 30 Jun 2025 Common 10,000 $0.9050 Direct F1
transaction LIXT Options to Purchase Common Stock Award $0 +11,632 $0.000000 11,632 30 Jun 2025 Common 11,652 $0.9050 Direct F2
holding LIXT Options to Purchase Common Stock 8,777 30 Jun 2025 Common 8,777 $1.21 Direct
holding LIXT Options to Purchase Common Stock 4,545 30 Jun 2025 Common 4,545 $2.33 Direct
holding LIXT Options to Purchase Common Stock 5,786 30 Jun 2025 Common 5,786 $1.30 Direct
holding LIXT Options to Purchase Common Stock 10,000 30 Jun 2025 Common 10,000 $2.37 Direct
holding LIXT Options to Purchase Common Stock 4,527 30 Jun 2025 Common 4,527 $2.37 Direct
holding LIXT Options to Purchase Common Stock 10,000 30 Jun 2025 Common 10,000 $7.45 Direct
holding LIXT Options to Purchase Common Stock 10,000 30 Jun 2025 Common 10,000 $30.30 Direct
holding LIXT Options to Purchase Common Stock 5,000 30 Jun 2025 Common 5,000 $32.10 Direct
holding LIXT Warrants to Purchase Common Stock 5,263 30 Jun 2025 Common 5,263 $57.00 By Sino-American Cancer FDD
holding LIXT Options to Purchase Common Stock 3,333 30 Jun 2025 Common 3,333 $16.80 Direct
holding LIXT Options to Purchase Common Stock 833 30 Jun 2025 Common 833 $66.00 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective June 30, 2025, the reporting person was granted stock options to purchase an aggregate of 10,000 shares vesting in eight equal installments on the last day of each subsequent quarter until fully vested with vesting to start on September 30, 2025.
F2 Effective June 30, 2025 the reporting person was granted stock options in aggregate of 11,632 vesting immediately. The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.